Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Director | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,571 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Grant · Acquired 2,465 · Balance 61,571 F1: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,995,958 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,995,958 F2: Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 377,542 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 377,542 F3: Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
F2: Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F3: Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 21:12 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 2,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-420639 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,571 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| July 10, 2026 Filed Jul 10, 2026 23:41 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 2,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-301167 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,106 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| April 10, 2026 Filed Apr 11, 2026 00:58 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 3,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-151632 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,254 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:11 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $5.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 4 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:11 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 3 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:11 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 20,724 | Not disclosed Strike: $17.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,724 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:11 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 20,724 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120226 · ownership.xml · derivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,724 Underlying: Common Stock · 20,724 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:21 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064059 · ownership.xml · derivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-02-19 F1 · derivative.exercise_date: The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 22:07 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 11,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-013041 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,479 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:01 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 10,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-238983 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,919 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 22:23 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 11,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095408 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,552 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:51 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Optin (Right to Buy) · Derivative | 19,111 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000950170-25-077035 · ownership.xml · derivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,111 Underlying: Common Stock · 19,111 shares Expires 2035-05-21 F1 · derivative.exercise_date: The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 21:03 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 9,705 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-053367 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,677 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 23:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 8,972 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139800 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,972 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 22:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 64,503 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076404 · ownership.xml · derivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,503 Underlying: Common Stock · 64,503 shares Expires 2034-06-18 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 15,907 | $19.65 | $312,572.55 |
DisclosureSEC source: 0000950170-24-005515 · ownership.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 377,542 F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 84,093 | $19.65 | $1,652,427.45 |
DisclosureSEC source: 0000950170-24-005515 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 1,995,958 F1 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 288 | $16.15 | $4,650.05 |
DisclosureSEC source: 0000950170-23-064609 · ownership.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P Disclosed balance after: 393,449 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,522 | $16.15 | $24,574.21 |
DisclosureSEC source: 0000950170-23-064609 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P Disclosed balance after: 2,080,051 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 23:21 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 902 | $16.07 | $14,495.14 |
DisclosureSEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 4 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 393,737 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 23:21 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 4,770 | $16.07 | $76,653.90 |
DisclosureSEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 3 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,081,573 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 23:21 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 15,764 | $16.28 | $256,637.92 |
DisclosureSEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 394,639 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 23:21 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 83,337 | $16.28 | $1,356,726.36 |
DisclosureSEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,086,343 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,356 | $16.11 | $21,845.16 |
DisclosureSEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 4 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P Disclosed balance after: 410,403 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 7,160 | $16.11 | $115,347.60 |
DisclosureSEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 3 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.( Disclosed balance after: 2,169,680 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 21:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 134 | $16.07 | $2,153.38 |
DisclosureSEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 411,759 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 21:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 707 | $16.07 | $11,361.49 |
DisclosureSEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,176,840 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 21:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 64 | $16.00 | $1,024.00 |
DisclosureSEC source: 0000950170-23-048436 · ownership.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P Disclosed balance after: 411,893 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 21:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 336 | $16.00 | $5,376.00 |
DisclosureSEC source: 0000950170-23-048436 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,177,547 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · ownership.nature: . Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 20:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 537 | $16.05 | $8,618.85 |
DisclosureSEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 4 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 411,957 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 20:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,841 | $16.05 | $45,598.05 |
DisclosureSEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 3 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,177,883 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 598 | $16.02 | $9,579.96 |
DisclosureSEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 412,494 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 3,164 | $16.02 | $50,687.28 |
DisclosureSEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,180,724 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:30 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 64 | $16.00 | $1,024.00 |
DisclosureSEC source: 0000950170-23-044593 · ownership.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 413,092 F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:30 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 336 | $16.00 | $5,376.00 |
DisclosureSEC source: 0000950170-23-044593 · ownership.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,183,888 F1 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 01:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0000899243-23-015326 · doc4.xml · derivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| June 06, 2022 Filed Jun 24, 2022 21:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | OtherCommon Stock | 26,511 | $15.00 | $397,665.00 |
DisclosureSEC source: 0000899243-22-024054 · doc4.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 413,156 F1 · kind: On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund") transferred to Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund. F1 · price: On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund") transferred to Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund. F3 · ownership.nature: Shares held directly by AGHT Fund DE. The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| June 06, 2022 Filed Jun 24, 2022 21:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | OtherCommon Stock | 26,511 | $15.00 | $397,665.00 |
DisclosureSEC source: 0000899243-22-024054 · doc4.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,184,224 F1 · kind: On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund") transferred to Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund. F1 · price: On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund") transferred to Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund. F2 · ownership.nature: Shares held directly by AGHT Fund. The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 20,724 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018282 · doc4.xml · derivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,724 Underlying: Common Stock · 20,724 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/36 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries B Convertible Preferred Stock · Derivative | 74,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · derivative · entry 9 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 0 Underlying: Common Stock · 74,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries B Convertible Preferred Stock · Derivative | 392,433 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · derivative · entry 8 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 392,433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries A Convertible Preferred Stock · Derivative | 312,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · derivative · entry 7 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 0 Underlying: Common Stock · 312,415 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,651,636 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · derivative · entry 6 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,651,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 166,666 | $15.00 | $2,499,990.00 |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · nonDerivative · entry 5 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,210,735 F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 74,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · nonDerivative · entry 4 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 386,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 392,433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · nonDerivative · entry 3 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 2,044,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 312,415 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · nonDerivative · entry 2 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P. Disclosed balance after: 312,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 1,651,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012988 · doc4.xml · nonDerivative · entry 1 Aziz Kabeer · CIK 0001914847 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P. Disclosed balance after: 1,651,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.